RxDoctor Payments Data

Jennifer McCullen, MD

Gynecology · Lakewood Ranch, FLNPI 1497756944

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.5% of the total across 191 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $782, 2.1 times the $368 reported in 2019.

$3,699in general payments, 2019–2025

Across 191 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mayne Pharma Commercial LLC$612
  • Astellas Pharma US Inc$540
  • AbbVie$368
  • Exact Sciences$219
  • Sumitomo Pharma America, Inc.$209
  • Pfizer$199
  • plus $2K from 30 others

What the payments were for

  • Food & beverage$3,42092%
  • Education$2798%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,699 in reported general payments places this provider in the 85th percentile of 290 gynecology providers in Florida.

See all gynecology providers in Florida

Medicare billing

Part B allowed, 2024
$59,009
Medicare patients
266
Services billed
782

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol156$8,413
PremarinEstrogens, Conjugated11$7,297
YuvafemEstradiol21$2,436
Betamethasone Valerate27$1,079
ProgesteroneProgesterone, Micronized39$923
Estradiol (Twice Weekly)Estradiol14$895
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst23$696
Metronidazole12$578
Clobetasol Propionate17$454
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip16$429
ValacyclovirValacyclovir Hcl32$334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$199$7,29711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 290 gynecology providers in Florida.

Other gynecology in Lakewood Ranch

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →